Poly Medicure (531768) Q3 25/26 earnings summary

Executive summary

• Transitioned to high-complexity, high-growth segments like cardiology-critical care and orthopedics, while maintaining a strong infusion business.

• Q3 FY26 consolidated revenue grew 16.4% YoY, with domestic up 16.2% and international up 16.6%.

• 19 new products launched in 9M FY26; R&D team expanded in India, Italy, and Netherlands.

• Received regulatory approvals for next-gen cardiovascular products (IVL and DEB); commercialization in India imminent.

• Board approved unaudited Q3 and 9M FY26 results, with no material misstatements in auditor review.

Financial highlights

• Q3 FY26 consolidated revenue: INR 494 crore, up 16.4% YoY; 9M revenue: INR 1,341 crore, up 9.1% YoY.

• Q3 gross profit: INR 338 crore, gross margin 68.4% (up 300 bps YoY).

• Q3 operating EBITDA: INR 119 crore (24.2% margin, excluding INR 6-7 crore acquisition costs).

• Q3 profit after tax: INR 71 crore, impacted by INR 6.8 crore in one-time labor code and acquisition expenses.

• Cash and cash equivalents at quarter-end: INR 840 crore.

Outlook and guidance

• H2 revenue expected to be 20% higher than H1; Q4 revenue guidance 9-10% above Q3.

• FY27 domestic business targeted to grow 25%, exports 12-15%; consolidated revenue growth expected at 20%+.

• Operating profit pool expected to grow in line with revenue.

• Enhanced healthcare budget and regulatory streamlining in India expected to support future growth.